Walleye Capital
LGND icon

Walleye Capital’s Ligand Pharmaceuticals LGND Stock Holding History

Walleye Capital’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-3,500
Closed -$375K – 4717
2024
Q4 		$375K Buy
3,500
+3,400
+3,400% +$384K ﹤0.01% 3229
2024
Q3 		$10K Buy
+100
New +$10.1K ﹤0.01% 4913
2024
Q1 		– Sell
-8,800
Closed -$628K – 5663
2023
Q4 		$628K Buy
8,800
+7,500
+577% +$443K ﹤0.01% 2762
2023
Q3 		$77.9K Buy
+1,300
New +$85.6K ﹤0.01% 4042
2023
Q1 		– Sell
-100
Closed -$6.68K – 4174
2022
Q4 		$6.68K Sell
100
-60
-38% -$3.9K ﹤0.01% 2817
2022
Q3 		$9K Buy
+160
New +$9.41K ﹤0.01% 2834
2019
Q4 		– Sell
-20,839
Closed -$1.29M – 2049
2019
Q3 		$1.29M Sell
20,839
-5,931
-22% -$372K 0.08% 350
2019
Q2 		$1.91M Buy
+26,770
New +$1.97M 0.21% 103

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return

Walleye Capital's LGND Position: Q1 2026 in Review

Walleye Capital opened a new position in Ligand Pharmaceuticals (LGND) in Q1 2026: 10,333 shares worth $2.06M. The stake represents 0.01% of the portfolio and ranks #1439 among its holdings. This is a return to the name: Walleye Capital previously reported a position in LGND as recently as Q4 2024.

Walleye Capital first reported a position in LGND in Q2 2022 and has held it in 8 quarters since. 357 funds tracked by Wall St. Rank hold LGND as of Q1 2026.

  • Walleye Capital held 10,333 shares of Ligand Pharmaceuticals worth $2.06M as of Q1 2026.
  • Ligand Pharmaceuticals was a new Walleye Capital position in Q1 2026.
  • Ligand Pharmaceuticals made up 0.01% of Walleye Capital's portfolio in Q1 2026, its #1439 holding.
  • Walleye Capital first reported a position in Ligand Pharmaceuticals in Q2 2022 and has held it in 8 quarters since.
  • 357 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2026.

Based on Walleye Capital's 13F filing for Q1 2026, filed 11 May 2026.